- 询价
- WYTSCI
- 进口
- WT-AY-B10985
- 2025年07月11日
1 年钻石会员
企业认证
相关产品推荐更多 >
万千商家帮你免费找货
0 人在求购买到急需产品
- 详细信息
- 文献和实验
- 技术资料
- 保存条件：
-20°C
- 保质期：
咨询
- 英文名：
Baricitinib
- 库存：
1000+
- 供应商：
上海维亦特生物
- CAS号：
1187594-09-7
纯度：98% by HPLC；NMR (Conforms)
分子式：C16H17N7O2S
分子量：371.42
溶剂：DMSO (30 mg/ml) DMF (50 mg/ml)
性状：White or off-white solid
存储：-20°C
Activity (short version)：JAK 1/2 inhibitor
Function / Pharmacology：Baricitinib, approved by the FDA for two inflammatory disorders, rheumatoid arthritis and alopecia areata, selectively inhibits Janus kinase 1 (IC50 = 5.9 nM) and 2 (5.7 nM), over 3 (0.56 µM).1 It thereby blocks JAK/STAT signaling, reducing cytokine release and suppressing the innate and adaptive immune systems.1,2 Was recently shown to significantly improve COVID-19 symptoms in a preliminary human trial, presumably through suppression of the cytokine release syndrome (“cytokine storm”) induced by SARS-CoV-2 infection.3
分子式：C16H17N7O2S
分子量：371.42
溶剂：DMSO (30 mg/ml) DMF (50 mg/ml)
性状：White or off-white solid
存储：-20°C
Activity (short version)：JAK 1/2 inhibitor
Function / Pharmacology：Baricitinib, approved by the FDA for two inflammatory disorders, rheumatoid arthritis and alopecia areata, selectively inhibits Janus kinase 1 (IC50 = 5.9 nM) and 2 (5.7 nM), over 3 (0.56 µM).1 It thereby blocks JAK/STAT signaling, reducing cytokine release and suppressing the innate and adaptive immune systems.1,2 Was recently shown to significantly improve COVID-19 symptoms in a preliminary human trial, presumably through suppression of the cytokine release syndrome (“cytokine storm”) induced by SARS-CoV-2 infection.3
风险提示：丁香通仅作为第三方平台，为商家信息发布提供平台空间。用户咨询产品时请注意保护个人信息及财产安全，合理判断，谨慎选购商品，商家和用户对交易行为负责。对于医疗器械类产品，请先查证核实企业经营资质和医疗器械产品注册证情况。
文献和实验该产品被引用文献
1187594-09-7
技术资料暂无技术资料 索取技术资料
文献支持
Baricitinib
询价
